# Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

> **NCT05065567** · PHASE3 · TERMINATED · sponsor: **Corewell Health South** · enrollment: 32 (actual)

## Conditions studied

- Cyclic Vomiting Syndrome

## Interventions

- **DRUG:** Droperidol
- **DRUG:** Haloperidol
- **DRUG:** Ondansetron 8mg

## Key facts

- **NCT ID:** NCT05065567
- **Lead sponsor:** Corewell Health South
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-30
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lost too many patients to follow up, unable to enroll enough patients
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05065567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05065567, "Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05065567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*